Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

FGEN

FibroGen Inc

May 17 • 04:00PM ET

1.20

Dollar change -0.04
Percentage change -3.23	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO VHT FESM VTWV IWV BTEC

Index	RUT	P/E	-	EPS (ttm)	-2.45	Insider Own	6.90%	Shs Outstand	98.77M	Perf Week	3.45%
Market Cap	119.38M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.73%	Shs Float	92.61M	Perf Month	2.56%
Income	-240.46M	PEG	-	EPS next Q	-0.32	Inst Own	61.93%	Short Float	7.47%	Perf Quarter	-45.21%
Sales	167.49M	P/S	0.71	EPS this Y	55.25%	Inst Trans	2.87%	Short Ratio	3.11	Perf Half Y	134.97%
Book/sh	-2.29	P/B	-	EPS next Y	56.12%	ROA	-53.17%	Short Interest	6.92M	Perf Year	-93.27%
Cash/sh	1.79	P/C	0.67	EPS next 5Y	-	ROE	-42790.17%	52W Range	0.33 - 19.47	Perf YTD	35.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.23%	ROI	-	52W High	-93.84%	Beta	0.84
Dividend TTM	-	Quick Ratio	1.27	Sales past 5Y	-2.51%	Gross Margin	75.46%	52W Low	260.04%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	1.41	EPS Y/Y TTM	25.09%	Oper. Margin	-133.85%	RSI (14)	45.46	Volatility	10.11% 13.54%
Employees	486	Debt/Eq	-	Sales Y/Y TTM	44.30%	Profit Margin	-143.56%	Recom	4.00	Target Price	1.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	58.93%	Payout	-	Rel Volume	0.59	Prev Close	1.24
Sales Surprise	52.47%	EPS Surprise	21.05%	Sales Q/Q	54.59%	Earnings	May 06 AMC	Avg Volume	2.22M	Price	1.20
SMA20	4.74%	SMA50	-24.67%	SMA200	1.60%	Trades		Volume	1,302,520	Change	-3.23%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45
Feb-01-21	Initiated	H.C. Wainwright	Buy	$58
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy	$71

Show Previous Ratings

May-07-24 10:15AM	FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +18.10%
08:57AM	Q1 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:00AM	FibroGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:14AM	Loading…
03:14AM	FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-24 08:58PM	FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:25PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%
Apr-03-24 09:32AM	Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak (FierceBiotech.com) -31.94%
Apr-02-24 05:46PM	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -8.47%
Mar-26-24 07:00AM	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.58%
Mar-20-24 03:45PM	3 Nightmare Nasdaq Stocks Not Worth Holding Another Day (InvestorPlace)
07:00AM	Loading…
Mar-11-24 07:00AM	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-29-24 08:09AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.85%
Feb-27-24 09:59AM	Q4 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 (GuruFocus.com)
04:34PM	UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:15PM	FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:06PM	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea (GlobeNewswire)
Feb-20-24 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -17.81%
Feb-05-24 07:00AM	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 (GlobeNewswire) +8.87%
Jan-25-24 07:00AM	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer (GlobeNewswire) +13.37%
Dec-09-23 05:02PM	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-07-23 11:01AM	FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:01AM	Q3 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
05:33PM	Loading…
Nov-06-23 05:33PM	FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue (GuruFocus.com) -13.62%
05:30PM	FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:10PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 07:00AM	FibroGen to Report Third Quarter 2023 Financial Results (GlobeNewswire) -7.77%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks) -24.23%
Aug-29-23 06:00PM	FibroGen's drug misses mark on yet another clinical trial (American City Business Journals)
04:15PM	FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-16-23 09:35AM	Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Aug-09-23 09:14AM	Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? (Simply Wall St.)
Aug-08-23 10:08AM	Q2 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -18.64%
08:59AM	FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:30PM	FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -7.33%
05:40PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	FibroGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:00AM	FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives (American City Business Journals) +7.29%
Jul-25-23 10:49AM	FibroGen CEO resigns after back-to-back drug study failures, job cuts (American City Business Journals) -5.74%
07:00AM	FibroGen Announces Leadership Transition (GlobeNewswire)
Jul-24-23 07:00AM	FibroGen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -5.41%
Jul-19-23 10:50AM	Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs (American City Business Journals) -7.03%
Jul-14-23 09:55AM	FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jul-11-23 09:35AM	Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Jul-01-23 08:46AM	Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? (Motley Fool)
Jun-27-23 12:45PM	FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study (Zacks) -7.38%
Jun-26-23 04:04PM	FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug (Investor's Business Daily) -83.12%
11:34AM	FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains (Simply Wall St.)
07:22AM	UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease (Reuters)
07:11AM	FibroGen's lung disease treatment fails in late-stage trial (Reuters)
07:04AM	FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-08-23 01:03PM	FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8% (Zacks)
Jun-07-23 04:03PM	FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost (Investor's Business Daily) -8.44%
11:47AM	FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal (Benzinga)
07:02AM	FibroGen's neuromuscular disease drug fails to meet main goal in late-stage study (Reuters)
06:55AM	FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-06-23 04:01PM	FibroGen to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
02:06PM	FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 (Investor's Business Daily)
May-18-23 07:30AM	FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia (GlobeNewswire)
May-09-23 10:22AM	Q1 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:12PM	FibroGen: Q1 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports First Quarter 2023 Financial Results (GlobeNewswire)
04:00PM	FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics (GlobeNewswire)
May-05-23 01:19PM	FibroGen, Inc. (NASDAQ:FGEN) Investors Are Less Pessimistic Than Expected (Simply Wall St.)
07:37AM	FibroGen's anemia drug fails to meet main goal in late-stage trial (Reuters)
07:30AM	FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS) (GlobeNewswire)
May-03-23 03:43AM	ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains? (Zacks)
May-01-23 07:00AM	FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value (GlobeNewswire)
Apr-24-23 07:00AM	FibroGen to Report First Quarter 2023 Financial Results (GlobeNewswire) -17.21%
Apr-03-23 07:00AM	FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Mar-24-23 10:21AM	FibroGen (NASDAQ:FGEN investor five-year losses grow to 60% as the stock sheds US$145m this past week (Simply Wall St.)
Mar-11-23 03:27AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-28-23 02:43PM	Q4 2022 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-23 05:25PM	FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
07:00AM	FibroGen to Present at Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-23-23 11:33AM	Should You Buy FibroGen (FGEN) Ahead of Earnings? (Zacks)
07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks)
Feb-22-23 10:00AM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-20-23 10:00AM	FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-17-23 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-02-23 07:00AM	FibroGen to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-16-23 09:34AM	With 73% ownership in FibroGen, Inc. (NASDAQ:FGEN), institutional investors have a lot riding on the business (Simply Wall St.)
Nov-28-22 07:00AM	FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference (GlobeNewswire)
Nov-09-22 05:15AM	FibroGen Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +6.78%
Nov-07-22 05:45PM	FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Third Quarter 2022 Financial Results (GlobeNewswire)
04:00PM	FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management (GlobeNewswire)

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wettig Thane	CEO	Mar 07 '24	Buy	1.91	50,000	95,470	470,178	Mar 11 07:06 PM
Henderson Jeffrey William	Director	Sep 01 '23	Sale	1.03	2,000	2,060	28,866	Sep 06 08:54 PM
Henderson Jeffrey William	Director	Aug 04 '23	Sale	1.91	2,000	3,820	30,866	Aug 08 07:10 PM
Henderson Jeffrey William	Director	Jul 11 '23	Sale	2.69	2,000	5,380	32,866	Jul 13 08:28 PM
Conterno Enrique A	Chief Executive Officer	Jul 07 '23	Sale	2.80	1,880	5,264	374,722	Jul 10 07:36 PM
Wettig Thane	Chief Commercial Officer	Jun 23 '23	Sale	16.53	791	13,075	108,261	Jun 26 04:27 PM
Chung Christine	SVP, China Operations	Jun 14 '23	Sale	16.79	6,250	104,925	236,327	Jun 15 08:17 PM
Chung Christine	SVP, China Operations	Jun 13 '23	Sale	17.60	6,250	110,000	242,577	Jun 15 08:17 PM
Blaug Suzanne	Director	Jun 09 '23	Sale	17.20	8,520	146,571	29,594	Jun 09 07:54 PM
EDWARDS JEFFREY L	Director	Jun 09 '23	Sale	17.19	7,889	135,622	33,977	Jun 09 07:53 PM
Brennan Aoife	Director	Jun 09 '23	Sale	17.19	4,733	81,367	27,947	Jun 09 07:55 PM
Cravatt Benjamin	Director	Jun 09 '23	Sale	17.17	3,944	67,717	28,736	Jun 09 07:56 PM
Ho Maykin	Director	Jun 08 '23	Sale	17.44	8,520	148,591	31,501	Jun 09 07:54 PM
Henderson Jeffrey William	Director	Jun 08 '23	Sale	17.46	7,000	122,185	34,866	Jun 09 07:52 PM
Conterno Enrique A	Chief Executive Officer	Jun 07 '23	Sale	17.04	8,897	151,583	376,602	Jun 09 07:10 PM
Schoeneck James A	Director	Jun 07 '23	Sale	18.03	7,100	127,987	73,722	Jun 09 07:51 PM
Chung Christine	SVP, China Operations	Jun 07 '23	Sale	17.04	3,633	61,894	248,827	Jun 09 07:38 PM
Eisner Mark	EVP, Chief Medical Officer	Jun 07 '23	Sale	17.04	2,042	34,792	162,862	Jun 09 07:12 PM
Graham Juan	Chief Financial Officer	Jun 07 '23	Sale	16.99	1,785	30,320	71,083	Jun 09 07:39 PM
Wettig Thane	Chief Commercial Officer	Jun 07 '23	Sale	17.04	1,758	29,951	111,395	Jun 09 07:39 PM
Eisner Mark	EVP, Chief Medical Officer	Jun 02 '23	Sale	18.83	1,090	20,525	164,904	Jun 05 04:22 PM

Open in Screener

HALO

Halozyme Therapeutics Inc.

May 17 • 04:00PM ET

44.71

Dollar change -0.68
Percentage change -1.50	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IJH VTI IWM VB VXF VBK IWO FBT IJK IBB

Index	RUT	P/E	18.49	EPS (ttm)	2.42	Insider Own	1.11%	Shs Outstand	126.77M	Perf Week	3.62%
Market Cap	5.69B	Forward P/E	9.87	EPS next Y	4.53	Insider Trans	-6.61%	Shs Float	125.86M	Perf Month	18.25%
Income	318.80M	PEG	0.71	EPS next Q	0.75	Inst Own	97.69%	Short Float	6.68%	Perf Quarter	23.85%
Sales	862.99M	P/S	6.59	EPS this Y	34.85%	Inst Trans	3.77%	Short Ratio	8.13	Perf Half Y	13.65%
Book/sh	1.40	P/B	31.98	EPS next Y	21.32%	ROA	18.01%	Short Interest	8.41M	Perf Year	33.62%
Cash/sh	3.64	P/C	12.28	EPS next 5Y	26.00%	ROE	261.68%	52W Range	31.86 - 46.16	Perf YTD	20.97%
Dividend Est.	-	P/FCF	13.43	EPS past 5Y	-	ROI	18.99%	52W High	-3.14%	Beta	1.28
Dividend TTM	-	Quick Ratio	5.36	Sales past 5Y	41.16%	Gross Margin	69.96%	52W Low	40.33%	ATR (14)	1.34
Dividend Ex-Date	-	Current Ratio	6.64	EPS Y/Y TTM	83.75%	Oper. Margin	43.95%	RSI (14)	68.43	Volatility	3.02% 3.05%
Employees	373	Debt/Eq	8.62	Sales Y/Y TTM	22.41%	Profit Margin	36.94%	Recom	1.36	Target Price	50.25
Option/Short	Yes / Yes	LT Debt/Eq	8.44	EPS Q/Q	107.45%	Payout	0.00%	Rel Volume	1.07	Prev Close	45.39
Sales Surprise	-1.93%	EPS Surprise	15.08%	Sales Q/Q	20.81%	Earnings	May 07 AMC	Avg Volume	1.03M	Price	44.71
SMA20	9.30%	SMA50	10.43%	SMA200	15.16%	Trades		Volume	1,102,058	Change	-1.50%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight	$18 → $27
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform	$17 → $24
Jan-08-20	Initiated	Goldman	Buy	$24

Show Previous Ratings

May-16-24 02:55PM	Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating (Investor's Business Daily)
09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
May-10-24 12:39PM	Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout (Investor's Business Daily)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire)
06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
03:10PM	Loading…
May-08-24 03:10PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:34AM	Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates (Zacks)
08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
07:05AM	Q1 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:52AM	Halozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-07-24 09:00PM	HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:00PM	Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:49PM	Halozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue Growth (GuruFocus.com)
05:48PM	Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed (MT Newswires)
05:25PM	Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates (Zacks)
04:23PM	Loading…
04:23PM	Halozyme Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
May-06-24 09:16AM	Halozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
May-03-24 04:17AM	How Novo-Catalent Deal Affects Halozyme (HALO)? (Insider Monkey)
Apr-30-24 10:01AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-24 04:45PM	Mahesh Krishnan Elected to Halozyme's Board of Directors (PR Newswire)
06:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition (InvestorPlace)
Apr-24-24 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Apr-23-24 08:30AM	Halozyme to Report First Quarter 2024 Financial and Operating Results (PR Newswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-04-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Mar-29-24 06:40AM	The 3 Best Biotech Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-21-24 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report? (Zacks)
09:40AM	Loading…
Mar-19-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Mar-14-24 01:24AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 02:05AM	Should You Hold Halozyme Therapeutics (HALO)? (Insider Monkey)
Mar-09-24 01:07PM	5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 03:15AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Feb-27-24 08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-21-24 11:26AM	Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag (Zacks) +6.56%
09:00AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 05:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics (Zacks)
05:10PM	Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates (Zacks)
04:36PM	Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ... (GuruFocus.com)
04:15PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Feb-14-24 09:15AM	Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
06:49AM	Halozyme Therapeutics (HALO) Underperformed Despite Strong Outlook (Insider Monkey)
Feb-13-24 10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-08-24 04:30PM	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results (PR Newswire)
Jan-29-24 04:15PM	Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Jan-26-24 09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jan-25-24 05:29PM	3 Biotech Stocks to Sell in January Before They Crash and Burn (InvestorPlace)
Jan-24-24 12:10PM	Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-22-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jan-18-24 05:01PM	Halozyme Therapeutics Inc's SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares (GuruFocus.com)
08:30AM	Halozyme Announces argenx Received Approval in Japan for VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE for Generalized Myasthenia Gravis (PR Newswire)
Jan-17-24 04:01AM	Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jan-16-24 08:15AM	Halozyme Announces Takeda Receives FDA Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire) +5.61%
01:15AM	Halozyme Announces Roche Receives European Commission Approval of Tecentriq SC with ENHANZE Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types (PR Newswire)
Jan-12-24 09:25AM	Halozyme to Host Investor Business Forum and Long-Term Outlook Call (PR Newswire)
Jan-10-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Dec-15-23 03:01PM	Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ... (GuruFocus.com)
Dec-14-23 12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks) -6.29%
Dec-08-23 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Dec-06-23 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report? (Zacks)
Dec-05-23 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-27-23 08:00AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Nov-20-23 12:45PM	Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now (Zacks)
Nov-17-23 07:03AM	Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ... (GuruFocus.com)
Nov-16-23 09:55AM	Can Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
09:00AM	Halozyme Announces argenx Receives European Commission Approval of VYVGART SC with ENHANZE for Generalized Myasthenia Gravis (PR Newswire)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace)
04:43PM	Under the Microscope: 3 Biotech Stocks Pioneering Tomorrows Cures (InvestorPlace)
Nov-08-23 05:19AM	3 Promising Biotech Stocks Flying Under the Radar (InvestorPlace) -5.28%
Nov-07-23 11:22AM	Q3 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.04%
11:21AM	Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag (Zacks)
11:06AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 06:00PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics (Zacks)
05:25PM	Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates (Zacks)
05:10PM	Halozyme Therapeutics Inc (HALO) Reports 15% YoY Increase in Q3 Royalty Revenue, Raises 2023 ... (GuruFocus.com)
04:27PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
07:30AM	Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE Technology in Alzheimer's Disease (PR Newswire)
Oct-30-23 06:35PM	Halozyme To Report Third Quarter 2023 Financial and Operating Results (PR Newswire)
Oct-27-23 08:47AM	Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune (InvestorPlace)
Oct-20-23 12:08PM	12 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
05:36AM	Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals (Zacks)
Oct-19-23 07:32AM	UPDATE 2-Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial (Reuters)
07:15AM	Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma (PR Newswire)
Oct-18-23 05:01AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ... (GuruFocus.com)
Oct-16-23 03:05PM	Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference (PR Newswire)
08:00AM	Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery (PR Newswire)
Oct-13-23 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Sep-20-23 05:01AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ... (GuruFocus.com)
Sep-07-23 11:30AM	Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound? (Zacks)
09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Sep-05-23 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Sep-01-23 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-31-23 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-30-23 07:17AM	Should You Remain Confident in Halozyme Therapeutics (HALO)? (Insider Monkey)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Sale	38.35	10,000	383,500	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 26 '24	Option Exercise	11.20	11,618	130,160	168,176	Mar 26 07:38 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Option Exercise	10.66	10,000	106,638	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Sale	42.27	10,000	422,730	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Option Exercise	12.07	10,000	120,700	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Sale	41.64	10,000	416,370	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Option Exercise	8.11	7,471	60,590	164,029	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Sale	39.55	10,000	395,463	156,558	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '24	Sale	39.95	10,000	399,460	159,087	Feb 28 06:49 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '24	Option Exercise	0.00	37,884	0	685,814	Feb 20 06:49 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Feb 16 '24	Option Exercise	0.00	4,796	0	14,257	Feb 20 06:55 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,422	0	18,344	Feb 20 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,376	0	171,247	Feb 20 06:59 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '24	Option Exercise	0.00	3,386	0	160,529	Feb 16 05:47 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '24	Option Exercise	0.00	1,254	0	11,345	Feb 16 05:41 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '24	Option Exercise	0.00	13,092	0	651,096	Feb 16 05:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 10 '24	Option Exercise	0.00	31,281	0	654,947	Feb 13 04:12 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 10 '24	Option Exercise	0.00	2,502	0	11,568	Feb 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 10 '24	Option Exercise	0.00	8,133	0	160,044	Feb 13 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Jan 03 '24	Option Exercise	0.00	7,611	0	12,418	Jan 05 04:04 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Option Exercise	12.07	10,000	120,700	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Sale	40.39	10,000	403,940	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Option Exercise	13.55	10,000	135,547	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Sale	39.63	10,000	396,322	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Option Exercise	13.81	10,000	138,100	161,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Sale	39.79	10,000	397,880	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Option Exercise	14.32	10,000	143,173	160,203	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Sale	39.08	10,000	390,790	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Option Exercise	19.98	10,000	199,800	161,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Sale	36.52	10,000	365,200	151,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Option Exercise	19.98	10,000	199,800	161,911	Sep 19 04:09 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Sale	39.10	10,000	390,980	151,911	Sep 19 04:09 PM
Torley Helen	PRESIDENT AND CEO	Aug 31 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 31 '23	Sale	42.82	10,000	428,170	623,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 30 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 30 '23	Sale	42.85	10,000	428,540	623,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 29 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 29 '23	Sale	42.40	10,000	424,020	623,666	Aug 31 05:35 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 22 '23	Option Exercise	19.68	10,000	196,778	159,986	Aug 23 05:08 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 22 '23	Sale	42.41	10,000	424,070	151,911	Aug 23 05:08 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '23	Sale	43.18	10,000	431,820	623,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 16 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 16 '23	Sale	43.53	10,000	435,320	623,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '23	Sale	43.77	10,000	437,680	623,666	Aug 17 05:29 PM
Daly James M	Director	Aug 14 '23	Sale	43.74	10,000	437,410	20,503	Aug 15 04:04 PM
Daly James M	Director	Aug 11 '23	Sale	43.71	10,000	437,110	30,503	Aug 15 04:04 PM
Torley Helen	PRESIDENT AND CEO	Jul 27 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 27 '23	Sale	43.79	10,000	437,900	623,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 26 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 26 '23	Sale	42.69	10,000	426,890	623,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 25 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 25 '23	Sale	42.80	10,000	427,960	623,666	Jul 27 04:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 18 '23	Option Exercise	15.30	20,000	306,098	151,911	Jul 19 04:10 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 18 '23	Sale	40.43	10,000	404,300	141,911	Jul 19 04:10 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 21 '23	Option Exercise	18.41	10,000	184,100	151,911	Jun 22 06:20 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 21 '23	Sale	36.00	10,000	360,000	141,911	Jun 22 06:20 PM

Open in Screener

QCOM

Qualcomm, Inc.

May 17 • 04:00PM ET

193.86

Dollar change +0.59
Percentage change 0.31	%

Technology • Semiconductors • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ IVV VTV VGT VIG SMH SOXX VYM

Index	NDX, S&P 500	P/E	26.05	EPS (ttm)	7.44	Insider Own	0.20%	Shs Outstand	1.11B	Perf Week	6.47%
Market Cap	216.35B	Forward P/E	17.11	EPS next Y	11.33	Insider Trans	-4.26%	Shs Float	1.11B	Perf Month	20.08%
Income	8.38B	PEG	2.31	EPS next Q	2.25	Inst Own	77.75%	Short Float	1.84%	Perf Quarter	26.96%
Sales	36.41B	P/S	5.94	EPS this Y	17.96%	Inst Trans	-0.30%	Short Ratio	2.51	Perf Half Y	50.37%
Book/sh	21.89	P/B	8.86	EPS next Y	13.91%	ROA	16.65%	Short Interest	20.47M	Perf Year	84.96%
Cash/sh	12.41	P/C	15.62	EPS next 5Y	11.29%	ROE	38.26%	52W Range	101.47 - 196.08	Perf YTD	34.04%
Dividend Est.	3.36 (1.73%)	P/FCF	17.66	EPS past 5Y	-	ROI	21.49%	52W High	-1.13%	Beta	1.28
Dividend TTM	3.20 (1.65%)	Quick Ratio	1.98	Sales past 5Y	11.93%	Gross Margin	55.80%	52W Low	91.05%	ATR (14)	4.49
Dividend Ex-Date	May 30, 2024	Current Ratio	2.65	EPS Y/Y TTM	-20.11%	Oper. Margin	24.85%	RSI (14)	73.08	Volatility	2.03% 2.29%
Employees	50000	Debt/Eq	0.63	Sales Y/Y TTM	-11.36%	Profit Margin	23.03%	Recom	1.95	Target Price	191.37
Option/Short	Yes / Yes	LT Debt/Eq	0.59	EPS Q/Q	35.65%	Payout	48.27%	Rel Volume	0.71	Prev Close	193.27
Sales Surprise	0.35%	EPS Surprise	4.92%	Sales Q/Q	1.23%	Earnings	May 01 AMC	Avg Volume	8.15M	Price	193.86
SMA20	10.88%	SMA50	12.79%	SMA200	39.23%	Trades		Volume	5,795,654	Change	0.31%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-24	Initiated	The Benchmark Company	Buy	$200
Apr-16-24	Initiated	Evercore ISI	In-line	$177
Feb-01-24	Reiterated	TD Cowen	Outperform	$160 → $170
Feb-01-24	Downgrade	Citigroup	Buy → Neutral	$160
Jan-23-24	Initiated	Cantor Fitzgerald	Neutral	$150
Jan-12-24	Upgrade	Citigroup	Neutral → Buy	$160
Dec-08-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$119 → $132
Aug-09-23	Downgrade	Daiwa Securities	Buy → Outperform	$125
Aug-03-23	Downgrade	Deutsche Bank	Buy → Hold	$130 → $121
Jul-25-23	Reiterated	Susquehanna	Positive	$135 → $145
Jul-24-23	Reiterated	UBS	Neutral	$120 → $130
Jul-20-23	Initiated	Wolfe Research	Outperform	$145
Mar-16-23	Upgrade	Susquehanna	Neutral → Positive	$130 → $140
Mar-02-23	Resumed	Raymond James	Mkt Perform
Jan-23-23	Upgrade	Barclays	Equal Weight → Overweight	$120 → $150
Dec-12-22	Downgrade	Wells Fargo	Equal Weight → Underweight	$105
Nov-16-22	Initiated	Credit Suisse	Outperform	$150
Oct-24-22	Initiated	HSBC Securities	Buy	$180
Oct-11-22	Reiterated	KeyBanc Capital Markets	Overweight	$220 → $170
Jul-29-22	Downgrade	DZ Bank	Buy → Hold	$150

Show Previous Ratings

May-17-24 10:15AM	Students Worldwide To Make Waves as FIRST Announces 2024-2025 Youth Robotics Season, FIRST DIVE Presented by Qualcomm Incorporated (ACCESSWIRE)
03:47AM	Samsung unveils its top five customers for 1Q24 (DigiTimes)
May-16-24 05:22PM	Qualcomm Insider Sold Shares Worth $1,539,081, According to a Recent SEC Filing (MT Newswires)
03:45PM	Ampere teams up with Qualcomm to launch an Arm-based AI server (TechCrunch)
03:15PM	Qualcomm Wireless Reach and Instituto Crescer Announce the Opening of Mobile Virtual Reality Laboratories and Expansion of the Student Always Connected Program in Goiânia (ACCESSWIRE)
03:15PM	Loading…
03:15PM	Qualcomm Wireless Reach and Instituto Crescer Announce the Opening of Mobile Virtual Reality Laboratories and Expansion of the Student Always Connected Program in Goiania (ACCESSWIRE)
12:36PM	Qualcomm, Ampere Collaborating to Develop AI Inferencing Solution (MT Newswires)
11:03AM	Ampere Computing pairs with Qualcomm on AI, unveils new chip (Reuters)
11:00AM	Chip Startup Ampere Teams Up With Qualcomm for AI Server Push (Bloomberg)
May-15-24 06:05PM	TaroWorks Is Seeking Humanitarian Aid Organizations Ready To Transform Their Field Operations With Last-Mile Mobile Technology. (ACCESSWIRE)
03:07PM	7 Cheap Nasdaq Stocks to Buy Now: May 2024 (InvestorPlace)
11:36AM	Smartphones Are About to Get an AI Boost. Here Are the Stocks to Play the Revolution. (Barrons.com)
06:00AM	Retire Before 50: 7 Must-Own Stocks for Accelerated Wealth Building (InvestorPlace)
05:41AM	Daiwa Securities Adjusts Price Target on Qualcomm to $210 From $175, Keeps Outperform Rating (MT Newswires)
May-14-24 02:23PM	Final Trades: Pfizer, Vertex, Freeport-McMoran and Qualcomm (CNBC TV)
06:00AM	Loading…
06:00AM	The AI All-Stars: 7 Stocks With Millionaire-Making Potential (InvestorPlace)
May-13-24 04:30PM	3 Cheap 5G Stocks to Buy Now: May 2024 (InvestorPlace)
03:56PM	Now Even Apple Wants to Make Data Center Chips! Which Are the 3 Best Chipmaker Stocks to Buy? (InvestorPlace)
01:19PM	Calls of the Day: Delta Air Lines, Netflix, Qualcomm, Intel, Huntington, Visa (CNBC TV)
07:51AM	12 Monthly Dividend Stocks with Over 5% Yield (Insider Monkey)
06:00AM	The 7 Best Dividend Stocks to Buy in May 2024 (InvestorPlace)
04:38AM	Qualcomm Taiwan challenge: pioneering AI innovation on edge devices (DigiTimes)
May-12-24 02:17PM	Forget Nvidia: Here's 1 Other Semiconductor Stock to Buy Instead (Motley Fool)
May-11-24 02:15PM	Missed Out on Nvidia? This Incredibly Cheap Semiconductor Stock Is Crushing Nvidia in a Key Market Right Now, and It Could Soar 55%. (Motley Fool)
12:03PM	Gogoro Inc. (NASDAQ:GGR) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:41AM	Stock Market Crash Alert: 3 Must-Buy Metaverse Stocks When Prices Plunge (InvestorPlace)
02:42AM	Insider Sale: CFO & COO Akash Palkhiwala Sells 3,000 Shares of Qualcomm Inc (QCOM) (GuruFocus.com)
May-10-24 04:30PM	Qualcomm Insider Sold Shares Worth $542,055, According to a Recent SEC Filing (MT Newswires)
03:07PM	CEVA, Inc. (NASDAQ:CEVA) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:05AM	With Apple entering the fight, the AI chip wars have gone nuclear (Yahoo Finance)
10:51AM	Loading…
10:51AM	Intel and Qualcomm Received Bearish News This Week (Motley Fool)
10:00AM	Qualcomm Is Undervalued (GuruFocus.com)
09:02AM	16 Biggest Publicly Traded AI Companies in the World (Insider Monkey)
06:06AM	Semiconductor Superstars: 3 Chip Stocks Powering the Tech Boom in 2024 (InvestorPlace)
May-09-24 10:41AM	Globalstar, Inc. (AMEX:GSAT) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:50AM	Here's Why Qualcomm (QCOM) is a Strong Momentum Stock (Zacks)
06:59AM	3 Game-Changing Tech Stocks to Buy for 5X Gains by 2030 (InvestorPlace)
06:20AM	Qualcomm Stock: To Buy or Not to Buy, That Is the Question (InvestorPlace)
06:15AM	Prediction: This Incredibly Cheap Semiconductor Stock Could Become the Next Nvidia (Motley Fool)
05:22AM	Apples iPad event was an AI teaser for its future (Yahoo Finance)
May-08-24 03:08PM	Intel, Qualcomm Likely to See 'Modest' Impact From Tightened US Export Controls on Huawei, Wedbush Says (MT Newswires)
02:08PM	Tech Stocks on the Move Today: Uber Technologies, Reddit, and More (Investopedia)
02:00PM	How Edge Devices Can Help Mitigate the Global Environmental Cost of Generative AI (ACCESSWIRE)
01:01PM	US Revokes Qualcomm, Intel Export Licenses to Huawei (MT Newswires)
12:46PM	Intel Revises Revenue Guidance After US Slaps New Restrictions on Chip Sales to China (Investopedia)
12:02PM	Top Midday Stories: Uber Posts Surprise Q1 Net Loss; Shopify Forecasts Q2 Revenue Growth Slowdown; US Prosecutors Probing Tesla for Potential Securities Fraud; Intel, Qualcomm Banned From Selling Chips to Huawei (MT Newswires)
10:49AM	US Revokes Intel, Qualcomm Licenses to Sell Chips to Huawei (Bloomberg)
10:22AM	Qualcomm says US revoked one of its export licenses for Huawei (Reuters)
08:47AM	Intel Sees Revenue Falling Below Midpoint on US Huawei Ban (Bloomberg)
08:18AM	The U.S. barred Intel and Qualcomm from selling chips to China's Huawei (Quartz)
08:00AM	These 2 Tech Stocks Just Declared Dividend Raises (Motley Fool)
07:30AM	3 Tech Stock Darlings to Scoop Up After Q2 earnings (InvestorPlace)
07:20AM	US Reportedly Revokes Qualcomm, Intel's Licenses for Exports to Huawei (MT Newswires)
06:00AM	US chip output to see massive growth by 2032: Industry leader (Yahoo Finance Video)
May-07-24 07:09PM	Luxury on a Budget: 12 Affordable Smartphones with Premium Features (Insider Monkey)
04:23PM	Apple releases new iPad Pro with M4 chip, teasing AI features (Yahoo Finance Video)
04:09PM	US revokes export licenses for Huawei's chip suppliers: FT (Yahoo Finance Video)
09:00AM	QUALCOMM Incorporated (QCOM) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:08AM	Argus Adjusts Price Target on Qualcomm to $205 From $180 (MT Newswires)
07:00AM	7 Timeless Value Stocks to Build Wealth Like Warren Buffett (InvestorPlace)
12:28AM	GaAs foundry AWSC enjoys strong demand for flagship smartphones (DigiTimes)
May-06-24 06:00AM	Qualcomms Smartphone Future Looks Brighter With AI (The Wall Street Journal)
May-04-24 06:18AM	3 Internet of Things (IoT) Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace)
May-03-24 05:55PM	Qualcomm Insider Sold Shares Worth $1,456,000, According to a Recent SEC Filing (MT Newswires)
10:41AM	Digi International Inc. (NASDAQ:DGII) Q2 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	How To Buy Stocks: Use 'Ants' Indicator To Spot Exceptional Demand (Investor's Business Daily)
06:30AM	Why It's Time to Pound the Table on Qualcomm Stock in 2024 (InvestorPlace)
04:58AM	Qualcomm sees smartphone demand surge, eyes AI PC market entry (DigiTimes)
May-02-24 10:26PM	Qualcomm CEO on automotive investments: 'As new cars are launched you'll start to see the benefits' (CNBC TV) +9.74%
09:40PM	Qualcomm, MediaTek unfazed by Huawei rebound (DigiTimes)
04:57PM	US STOCKS-Wall Street ends higher as Fed signals dovish bias; jobs report eyed (Reuters)
04:27PM	These Stocks Are Moving the Most Today: Carvana, Fastly, Peloton, Wayfair, Qualcomm, Moderna, Howmet, Apple, Qorvo, and More (Barrons.com)
04:25PM	Three-Stock Lunch: Carvana, Qualcomm (CNBC TV)
04:13PM	Qualcomm Stock Breaks Out On Beat-And-Raise Report (Investor's Business Daily)
02:38PM	US STOCKS-Wall Street gains as Fed signals dovish bias; jobs report eyed (Reuters)
12:58PM	Qualcomm (QCOM) Stock Trades Up, Here Is Why (StockStory)
12:35PM	US STOCKS-Wall Street gains on Fed's dovish signals (Reuters)
12:29PM	Qualcomm, Carvana rise; DoorDash, Qorvo fall, Thursday, 5/2/2024 (Associated Press Finance)
12:19PM	Chip Stocks Get a Lift From Qualcomm (Barrons.com)
12:12PM	Stocks to Watch Thursday: Carvana, NIO, Qualcomm, Peloton (The Wall Street Journal)
12:03PM	Qualcomm CFO details 'first steps' of AI integration in phones (Yahoo Finance Video)
11:57AM	QUALCOMM Incorporated (NASDAQ:QCOM) Q2 2024 Earnings Call Transcript (Insider Monkey)
11:30AM	UBS Adjusts Price Target on Qualcomm to $175 From $165, Maintains Neutral Rating (MT Newswires)
11:11AM	Semiconductor stocks: What mixed results signal for the sector (Yahoo Finance Video)
10:37AM	Qualcomm Rises the Most in Two Years After Giving Rosy Forecast (Bloomberg)
10:37AM	Nvidia Stock Recovers After a Bad Day. 2 Things Boosting Shares. (Barrons.com)
10:32AM	US STOCKS-Wall Street rises as Fed rate-hike concerns alleviate (Reuters)
09:53AM	Qualcomm posts Q1 beat, upbeat guidance on smartphone demand (Yahoo Finance Video)
08:54AM	Qualcomm (QCOM) Q2 Earnings Top on Solid Automotive Revenues (Zacks)
08:02AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:30AM	Apple earnings on tap, investors digest Fed decision: Yahoo Finance (Yahoo Finance Video)
07:25AM	Qualcomm jumps as AI sparks rebound in Chinese smartphone market (Reuters)
07:10AM	Why Markets Must Beware Powells Comments on Fed Rate Hikes (Barrons.com)
07:03AM	Why Markets Must Beware Powells Comments on Fed Rate Hikes, and 5 Other Things to Know Today (Barrons.com)
06:52AM	Baird Adjusts Price Target on Qualcomm to $200 From $160 (MT Newswires)
06:47AM	Q2 2024 Qualcomm Inc Earnings Call (Thomson Reuters StreetEvents)
06:07AM	Bernstein Adjusts Price Target on Qualcomm to $220 From $200, Keeps Outperform Rating (MT Newswires)
06:04AM	Mizuho Adjusts Price Target on Qualcomm to $180 From $160, Keeps Buy Rating (MT Newswires)
06:03AM	Deutsche Bank Adjusts Price Target on Qualcomm to $155 From $145, Keeps Hold Rating (MT Newswires)
06:03AM	Citigroup Adjusts Price Target on Qualcomm to $170 From $160, Keeps Neutral Rating (MT Newswires)

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AMON CRISTIANO R	President & CEO	May 15 '24	Sale	190.01	8,100	1,539,081	0	May 16 05:19 PM
ACEVEDO SYLVIA	Director	May 10 '24	Sale	181.52	744	135,074	0	May 13 04:53 PM
AMON CRISTIANO R	President & CEO	May 09 '24	Sale	181.00	8,100	1,466,100	8,100	May 10 04:29 PM
Palkhiwala Akash J.	CFO & COO	May 09 '24	Sale	180.69	3,000	542,055	66,343	May 10 04:29 PM
THOMPSON JAMES H	Chief Technology Officer	May 03 '24	Sale	182.00	8,000	1,456,000	253,893	May 03 05:54 PM
ACEVEDO SYLVIA	Director	May 03 '24	Sale	178.21	2,056	366,400	54	May 06 04:24 PM
Palkhiwala Akash J.	CFO & COO	Apr 04 '24	Sale	173.49	3,000	520,480	69,343	Apr 04 07:35 PM
THOMPSON JAMES H	Chief Technology Officer	Apr 01 '24	Sale	168.27	8,000	1,346,160	261,893	Apr 02 04:13 PM
ACEVEDO SYLVIA	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	2,110	Mar 11 05:10 PM
MCLAUGHLIN MARK D	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	23,428	Mar 11 05:08 PM
LIVERMORE ANN M	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	32,873	Mar 11 05:08 PM
Johnson Gregory N	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	3,147	Mar 11 05:09 PM
Henderson Jeffrey William	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	6,408	Mar 11 05:09 PM
Miller Jamie S	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	4,159	Mar 11 05:08 PM
AMON CRISTIANO R	President & CEO	Mar 07 '24	Sale	169.60	8,100	1,373,760	16,200	Mar 08 04:10 PM
Palkhiwala Akash J.	CFO & COO	Mar 07 '24	Sale	175.02	7,000	1,225,118	72,343	Mar 11 04:54 PM
MARTIN NEIL	SVP, Finance and CAO	Mar 05 '24	Sale	160.64	689	110,680	0	Mar 05 06:18 PM
AMON CRISTIANO R	President & CEO	Mar 01 '24	Sale	159.50	8,100	1,291,950	24,300	Mar 01 06:25 PM
THOMPSON JAMES H	Chief Technology Officer	Mar 01 '24	Sale	159.39	8,000	1,275,120	269,893	Mar 01 06:40 PM
MARTIN NEIL	SVP, Finance and CAO	Feb 21 '24	Sale	149.83	371	55,587	689	Feb 21 04:57 PM
MARTIN NEIL	SVP, Finance and CAO	Feb 20 '24	Option Exercise	0.00	1,172	0	1,513	Feb 21 04:57 PM
AMON CRISTIANO R	President & CEO	Jan 19 '24	Sale	149.50	8,100	1,210,950	32,400	Jan 19 05:28 PM
CATHEY JAMES J	Chief Commercial Officer	Jan 11 '24	Sale	139.00	1,000	139,000	4,972	Jan 11 05:35 PM
AMON CRISTIANO R	President & CEO	Dec 15 '23	Option Exercise	0.00	23,426	0	244,182	Dec 18 05:55 PM
CHAPLIN ANN C	General Counsel&Corp Secretary	Dec 15 '23	Option Exercise	0.00	4,971	0	12,333	Dec 18 05:53 PM
CATHEY JAMES J	Chief Commercial Officer	Dec 15 '23	Option Exercise	0.00	3,715	0	7,779	Dec 18 05:54 PM
ACE HEATHER S	Chief Human Resources Officer	Dec 15 '23	Option Exercise	0.00	3,806	0	27,880	Dec 18 05:54 PM
THOMPSON JAMES H	Chief Technology Officer	Dec 15 '23	Option Exercise	0.00	10,542	0	283,522	Dec 18 05:53 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Dec 15 '23	Option Exercise	0.00	7,024	0	35,496	Dec 18 05:53 PM
Palkhiwala Akash J.	Chief Financial Officer	Dec 15 '23	Option Exercise	0.00	8,200	0	83,315	Dec 18 05:53 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Dec 14 '23	Sale	140.50	12,972	1,822,535	28,472	Dec 15 04:14 PM
CATHEY JAMES J	Chief Commercial Officer	Dec 11 '23	Sale	134.51	1,000	134,510	4,450	Dec 12 04:04 PM
MARTIN NEIL	SVP, Finance and CAO	Nov 29 '23	Sale	130.00	3,098	402,740	247	Nov 29 05:50 PM
MARTIN NEIL	SVP, Finance and CAO	Nov 20 '23	Option Exercise	0.00	4,736	0	4,983	Nov 21 05:09 PM
CATHEY JAMES J	Chief Commercial Officer	Nov 20 '23	Option Exercise	0.00	2,916	0	6,661	Nov 21 05:09 PM
CATHEY JAMES J	Chief Commercial Officer	Nov 13 '23	Sale	124.00	1,000	124,000	3,745	Nov 13 04:29 PM
THOMPSON JAMES H	Chief Technology Officer	Nov 09 '23	Sale	120.11	10,000	1,201,132	243,795	Nov 09 07:48 PM
CHAPLIN ANN C	General Counsel&Corp Secretary	Nov 01 '23	Option Exercise	0.00	5,701	0	9,333	Nov 02 04:27 PM
CATHEY JAMES J	Chief Commercial Officer	Oct 11 '23	Sale	112.28	1,000	112,280	4,745	Oct 11 04:52 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Oct 02 '23	Sale	110.40	6,001	662,510	25,229	Oct 02 06:35 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Oct 01 '23	Option Exercise	0.00	11,662	0	35,392	Oct 02 06:35 PM
ACE HEATHER S	Chief Human Resources Officer	Oct 01 '23	Option Exercise	0.00	2,869	0	17,152	Oct 02 06:23 PM
AMON CRISTIANO R	President & CEO	Oct 01 '23	Option Exercise	0.00	29,585	0	201,693	Oct 02 06:23 PM
Palkhiwala Akash J.	Chief Financial Officer	Oct 01 '23	Option Exercise	0.00	10,486	0	65,181	Oct 02 06:35 PM
THOMPSON JAMES H	Chief Technology Officer	Oct 01 '23	Option Exercise	0.00	20,990	0	262,359	Oct 02 06:35 PM
THOMPSON JAMES H	Chief Technology Officer	Sep 13 '23	Sale	113.23	27,962	3,166,098	241,369	Sep 13 06:33 PM
CATHEY JAMES J	Chief Commercial Officer	Sep 11 '23	Sale	111.27	1,000	111,270	5,745	Sep 11 04:36 PM
MARTIN NEIL	SVP, Finance and CAO	Aug 17 '23	Sale	110.19	4,752	523,623	247	Aug 18 04:22 PM
CATHEY JAMES J	Chief Commercial Officer	Aug 11 '23	Sale	114.16	1,000	114,160	6,745	Aug 11 05:40 PM
CATHEY JAMES J	Chief Commercial Officer	May 20 '23	Option Exercise	0.00	7,443	0	10,159	May 22 05:04 PM
ACE HEATHER S	Chief Human Resources Officer	May 20 '23	Option Exercise	0.00	7,198	0	16,772	May 22 05:04 PM
MARTIN NEIL	SVP, Finance and CAO	May 20 '23	Option Exercise	0.00	2,204	0	5,665	May 22 05:04 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

FGEN

FibroGen Inc

HALO

Halozyme Therapeutics Inc.

QCOM

Qualcomm, Inc.

Upgrade your FINVIZ experience